A revolutionary artificial intelligence tool is set to transform how abiraterone is selected for prostate cancer patients, by accurately predicting which men will benefit most from this drug that can halve the risk of death. This “gamechanger” treatment has already profoundly impacted men with advanced prostate cancer, but its wider adoption for earlier-stage disease has been limited in certain healthcare systems.
Developed through an international collaboration involving the US, UK, and Switzerland, the AI tool meticulously examines tumor images to uncover subtle biomarkers invisible to the human eye. This allows for unparalleled accuracy in predicting patient response to abiraterone, ensuring optimal treatment selection and resource allocation.
The unveiling of this groundbreaking AI test took place at the prestigious American Society of Clinical Oncology annual meeting in Chicago. Professor Nick James, co-leader of the research, highlighted the importance of this tool in balancing the “spectacular” benefits of abiraterone with its potential side effects, such as cardiovascular complications and liver abnormalities, making targeted therapy a priority.
In a comprehensive trial involving more than 1,000 men with high-risk, non-metastatic prostate cancer, the AI test successfully identified a critical 25% of patients for whom abiraterone reduced the five-year mortality risk from 17% to 9%. For the remaining 75% of men, whose tumors were “biomarker-negative,” the drug offered no statistically or clinically significant benefit, demonstrating the AI’s power to optimize treatment and avoid unnecessary interventions.